To investigate SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma (MM) and assess their clinical characteristics, highlighting the significance of these findings in the context of existing literature.
Key Findings:
All patients were fully vaccinated with BNT162b2 and developed SARS-CoV-2 infection after a median of 86 days post-vaccination, with implications for the timing of booster doses.
Patients exhibited varying symptoms, with some being asymptomatic and others experiencing mild to moderate symptoms, indicating a spectrum of clinical presentations.
Viral genotyping revealed the presence of Delta variant in four patients and Alpha variant in one patient, underscoring the need for ongoing surveillance of variants.
Interpretation:
The findings indicate that fully vaccinated MM patients remain at risk for SARS-CoV-2 infection, highlighting the urgent need for ongoing monitoring and potential booster vaccinations to enhance protection.
Limitations:
Small sample size limits generalizability of findings.
Lack of long-term follow-up data on the patients' immune responses post-infection.
Limited diversity in the patient cohort may affect the applicability of results to the broader MM population.
Conclusion:
Despite vaccination, patients with MM can still contract SARS-CoV-2, underscoring the importance of continued vigilance and research into vaccine efficacy in this population, particularly regarding booster strategies.
